Wall Street Is All Mixed Up About Teva Pharmaceutical; Jami Rubin Cuts Price Target


The market has divided itself into two camps. The bulls argue that the worst is behind Teva Pharmaceutical (NYSE:TEVA) as it started focusing on getting the business growing again. The bears argue that the market is too optimistic about Teva’s recovery, which could take a long, long time. Goldman Sachs analyst Jami Rubin has found himself in the middle.

Story Continues